LAB eN 2, the drug discovery accelerator launched by Evotec and Novo Nordisk in September 2023, has unveiled its first three ...

Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss ...

Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and ...

Thursday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has supported label update for weight-loss drug Ozempic to include kidney disease risk ...

The EMA approved a kidney disease–related label expansion for the blockbuster GLP-1 drug after a study showed reduced risk of ...

Ten universities are collaborating on a national effort to create an obesity curriculum for medical schools, addressing the need for comprehensive training ...

EU regulator supports a label expansion of Novo Nordisk’s diabetes drug to reflect its potential to lower the risk of ...

During the quarter, the Harbor International Compounders Fund returned 4.40%, underperforming its primary benchmark.

The European Medicines Agency (EMA) will allow Novo Nordisk to add risk reduction for events related to kidney disease to the ...

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

In the third quarter of its fiscal year 2025, ended Oct. 31, Veeva Systems' revenue increased by 13% year over year to $699.2 ...

Struggles with obesity are a longstanding issue for millions of Americans and thousands of Iowans, but recent advancements in ...